 Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.It is given in a clinic by intravenous (IV) infusion.Side effects include a risk for meningococcal infections and it is only prescribed to those who have enrolled in and follow a risk evaluation and mitigation strategy, which involves counseling people and ensuring that they are vaccinated.